This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Peptide Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018

DUBLIN, Dec. 16, 2013 /PRNewswire/ --  Research and Markets ( has announced the addition of the "Peptide Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018" report to their offering. therapeutics is currently offering a new commercial potential to pharmaceuticals and biotechnology industry. To exploit this emerging market, large pharmaceutical and biotechnological firms are actively investing in development of newer peptides for various applications and are also opting for newer technologies for syntheses of these peptides. Cancer is the leading cause of death globally; according to the WHO (World Health Organization), around 12.7 million new cancer cases occurred in the year 2008. About 7 million people die from cancer every year and it is estimated that there will be more than 16 million new cancer cases every year by 2020. With rise in cancer patients and metabolic diseases like diabetes, there has been a push in growth for peptide molecules since chemotherapy, which is the major mode of treatment for cancer, is facing major challenges due to its inability to deliver the correct amount of drug directly. In addition, it affects the normal cells in the body. Likewise, peptide application in various other treatments has opened a promising avenue for future growth of this market. New routes of peptide administration are being investigated; however the parenteral route continues to dominate this market and accounted for a share of almost 86% of the entire market. Similarly, the technology market is ruled by LPPS (long phase peptide syntheses) and is anticipated to decline owing to huge demand for solid phase peptide syntheses and hybrid syntheses.This report analyzes the peptide therapeutics market by types of applications (cancer, metabolic, neurological diseases and others), route of administration, by types (innovative and generic), by API therapeutics market (in-house vs. CMO), by peptide therapeutics, and technology. Each of these markets is analyzed by studying the current and future market scenario, with estimation for the period 2010 - 2018 in terms of value in USD million. Key Topics Covered: 1 Introduction1.1 Report description1.2 Market segmentation1.3 Scope of the report1.4 Research methodology1.5 Assumptions2 Executive Summary3 Global Peptide Therapeutics Market Dynamics3.1 Overview3.2 Drivers3.3 Restraints & challenges3.4 Opportunities3.5 Porters five forces analysis3.6 Market attractiveness analysis3.7 Peptide therapeutics - emerging technologies & trends3.8 Regulatory policies4 Global Peptide Therapeutics Market Analysis, By Applications5 Global Peptide Therapeutics Market, by Route of Administration5.1 Introduction5.2 Parenteral Route5.3 Oral Route5.4 Pulmonary Route5.5 Mucosal Route5.6 Others (Intradermal & Nasal)6 Peptide Therapeutics Market - Generic & Innovative Segments6.1 Introduction6.2 Peptide Therapeutics - Innovative market6.3 Peptide Therapeutics - Generic market7 API Peptide Therapeutics Market, In-house Vs CMO7.1 Introduction7.2 API peptide therapeutics - In-house market7.3 Contract Manufacturing Organizations (CMO)8 Peptide Therapeutics Market, By Technology8.1 Introduction8.2 Solid Phase Peptide Synthesis (SPPS)8.3 Liquid Phase Peptide Synthesis (LPPS)8.4 Hybrid Technology9 Peptide Therapeutics Market, By Geography9.1 Introduction9.2 North America9.3 Europe9.4 Asia 9.5 Rest of World10 Market Share Analysis10.1 Market share by key players10.2 Market share by key players in peptide drugs market10.3 Market share by key players in CMO segment11 Recommendations11.1 Success strategies11.2 Barriers to be considered12 Company Profiles Companies Mentioned:
  • Amgen, Inc.
  • Amylin Pharmaceuticals LLC Bristol-Myers Squibb (BMS)
  • AstraZeneca PLC
  • Bachem Holding AG
  • Eli Lilly and Company
  • GlaxoSmithKline (GSK)
  • Ipsen
  • Lonza Inc.
  • Merck & Co.
  • Novartis AG
  • Novo-Nordisk A/S
  • Peptisyntha
  • Pfizer, Inc.
  • PolyPeptide Group.
  • Roche
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceuticals

For more information visit

Media Contact:

Laura Wood , +353-1-481-1716,

SOURCE Research and Markets

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs